The clinical and translational research program at NYU Langone’s Dysautonomia Center aims to advance the understanding of autonomic disorders and develop specific treatments that improve quality of life and survival through evidence-based medicine.

Our clinical trials include both disease-modifying therapies, which target underlying causes of disease and aim to preserve function and prolong survival, as well as symptomatic treatments, which target specific symptoms to reduce their burden on patients’ lives. Our observational clinical trials translate clinical and laboratory findings into new, more effective treatments for people with autonomic disorders.

Translational research uses clinical expertise to create new diagnostic tools, identify biomarkers of disease progression, and develop novel drugs. By focusing on the prodromal phase of neurologic disorders, we are able to use new technologies to determine early alterations in both the brain and the blood, providing clues to underlying causes of disease and ultimately help guide drug discovery.

Autonomic Disorders Consortium

The Dysautonomia Center is a member of the Autonomic Disorders Consortium, a National Institutes of Health–funded initiative to bring new therapies to patients with rare autonomic disorders. The center was a founding member of the Autonomic Disorders Consortium, which brings together expert sites in a collaborative effort. Founded in 2009, the Autonomic Disorders Consortium connects patient support groups with physicians and investigators in the medical centers where these patients are seen to discover ways to treat and cure these disorders.

Amyloidosis Program

The autonomic nervous system is a target for amyloid deposition. Usually, patients have severe autonomic dysfunction at the time of diagnosis. A complete evaluation for patients is offered at the Dysautonomia Center, along with specific treatment for the autonomic manifestations. Ongoing clinical trials are performed as part of NYU Langone’s Amyloidosis Program.